Akums Drugs and Pharmaceuticals IPO (Akums Drugs and Pharmaceuticals Limited IPO)
Akums Drugs and Pharmaceuticals IPO open for bidding on 30th July 2024 and ends on 1st August 2024.
Akums Drugs and Pharmaceuticals Limited, established in 2004, is a leading contract manufacturing pharmaceutical company in India. Serving over 450 clients, including top pharmaceutical firms, Akums operates nine state-of-the-art manufacturing facilities. The company offers over 12,000 formulations across various therapeutic categories, ensuring high-quality production and compliance with international standards.
Akums’ robust R&D center develops innovative formulations, enhancing its leadership in pharmaceutical manufacturing. The company has a strong presence both domestically and internationally, supplying products to numerous markets globally.
Looking ahead, Akums aims to expand manufacturing capacities, diversify product offerings, and enter new therapeutic segments. The company plans to increase its global footprint by tapping into emerging markets and strengthening its presence in existing ones.
For more details refer to Akums Drugs IPO RHP and Akums Drugs IPO Pulse Score
Akums Drugs IPO Details
| IPO Date | 30th July 2024 to 1st August 2024 |
| Listing Date | 6th August 2024 |
| Face Value | ₹2 per share |
| Price Band | ₹646 to ₹679 per share |
| Lot Size | 22 Shares |
| Total Issue Size | 2,73,68,151 shares (aggregating up to ₹1,856.74 Cr) |
| Fresh Issue | 1,00,37,716 shares (aggregating up to ₹680.00 Cr) |
| Offer for Sale | 1,73,30,435 shares of ₹2 (aggregating up to ₹1,176.74 Cr) |
| Employee Discount | ₹64 per Share |
| Issue Type | Book Built Issue IPO |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| Anchor Investor | 1,22,05,912(44.6%) |
| QIB | 81,37,276(29.7%) |
| NII | 40,68,637(14.9%) |
| bNII | 27,12,425(9.9%) |
| sNII | 13,56,212(5%) |
| Retail | 27,12,424(9.9%) |
| Employees | 2,43,902(0.9%) |
| Total | 2,73,68,151(100%) |
Akums Drugs IPO Timeline
| IPO Open | 30th July 2024 |
| IPO Close | 1st August 2024 |
| Basis Of Allotment | 2nd August 2024 |
| Initiation of Refunds | 5th August 2024 |
| Credit of Shares to Demat | 5th August 2024 |
| Listing Date | 6th August 2024 |
Fundamentals
Data as of 31st March 2024
| Market Cap | ₹ 10,685.5 Cr | P/E Ratio- Pre IPO | |
| RoNW | -0.57% | P/E Ratio- Post IPO | |
| RoCE | 3.37% | P/B Ratio | 13.69 |
| Debt to Equity | 0.69 | PAT Margin% | 0.02% |
Akums Drugs IPO Objectives
The company proposes to utilize the Net Proceeds towards the funding of the following objects:
- Repayment/ prepayment of indebtedness of the Company;
- Repayment/ prepayment of indebtedness of the Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited;
- Funding incremental working capital requirements of the Company;
- Pursuing inorganic growth initiatives through acquisitions; and
- General Corporate Purposes.
Leave a Reply